PYC Therapeutics Launches $653M Equity Raise to Advance Four RNA Drug Candidates

• 3-for-5 pro-rata accelerated non-renounceable entitlement offer at $1.50 per share
• Total capital raise up to approximately A$653 million including a US specialist placement
• Funds to support registrational trials and first-in-human studies for four RNA drug candidates
• Offer underwritten up to A$200 million conditional on minimum $400 million raised in placement and institutional offer